In a welcome move, DexCom stock saw its Relative Strength Rating rise from 70 to 77 on Tuesday.
As you try to find the best stocks to buy and watch, keep a close on eye on relative price strength.
IBD's proprietary RS Rating tracks technical performance by showing how a stock's price action over the last 52 weeks compares to that of the other stocks in our database.
History reveals that the stocks that go on to make the biggest gains typically have an 80 or higher RS Rating as they begin their largest price moves. See if DexCom stock can continue to rebound and clear that threshold.
See How IBD Helps You Make More Money In Stocks
Is DexCom Stock A Buy?
DexCom stock is working on a cup without handle with a 139.55 entry. This pattern has a high success rate when the stock breaks out. See if the medical device stock can break out in heavy volume.
Earnings growth dropped in the most recent report from 100% to 79%. But revenue gains moved higher, from 25% to 27%.
DexCom stock holds the No. 3 rank among its peers in the Medical-Products industry group. Lantheus Holdings and DexCom are also among the group's highest-rated stocks.
